Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients

被引：0
|
作者：
Singh, Dave [1 ]
Govoni, Mirco [2 ]
Bassi, Michele [2 ]
Beeh, Kai Michael [3 ]
Colgan, Brendan [4 ]
Kornmann, Oliver [5 ]
Laeker, Brian [6 ]
Watz, Henrik [7 ]
Lucci, Germano [2 ]
Geraci, Silvia [2 ]
Rocco, Emanuele Calabro [2 ]
Emirova, Aida [8 ]
Nandeuil, Marie Anna [8 ]
机构：
[1] Univ Manchester, Med Evaluat Unit, Manchester, Lancs, England
[2] Chiesi Farmaceut SpA, Global Clin Dev, Parma, Italy
[3] Insaf Resp Res Inst, Wesbaden, Germany
[4] Celerion, Belfast, Antrim, North Ireland
[5] IKF Pneumol Frankfurt, Clin Res Ctr Resp Dis, Frankfurt, Germany
[6] Heart Lung Ctr, London, England
[7] Lung Clin, Pulm Res Inst, Grosshansdorf, Germany
[8] Chiesi SAS, Global Clin Dev, Bois Colombes, France
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
Biomarkers; COPD; -; management; Anti-inflammatory;
D O I：
10.1183/13993003.congress-2019.PA2044
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA2044
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
    Field, Stephen K.
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2011, 5 : 57 - 70
  • [42] Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent
    Huetten, Matthias C.
    Fehrholz, Markus
    Konrad, Franziska M.
    Ophelders, Daan
    Kleintjes, Clementine
    Ottensmeier, Barbara
    Spiller, Owen Brad
    Glaser, Kirsten
    Kramer, Boris W.
    Kunzmann, Steffen
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2019, 32 (06) : 396 - 404
  • [43] The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma
    Leaker, Brian R.
    Singh, Dave
    Ali, Ferhana Y.
    Barnes, Peter J.
    O'Connor, Brian
    BMC PULMONARY MEDICINE, 2014, 14
  • [44] CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration-In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window
    Villetti, Gino
    Carnini, Chiara
    Battipaglia, Loredana
    Preynat, Laurent
    Bolzoni, Pier Tonino
    Bassani, Franco
    Caruso, Paola
    Bergamaschi, Marco
    Pisano, Anna Rita
    Puviani, Veronica
    Stellari, Fabio Franco
    Cenacchi, Valentina
    Volta, Roberta
    Bertacche, Vittorio
    Mileo, Valentina
    Bagnacani, Valentina
    Moretti, Elisa
    Puccini, Paola
    Catinella, Silvia
    Facchinetti, Fabrizio
    Sala, Angelo
    Civelli, Maurizio
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 352 (03): : 568 - 578
  • [45] The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma
    Brian R Leaker
    Dave Singh
    Ferhana Y Ali
    Peter J Barnes
    Brian O’Connor
    BMC Pulmonary Medicine, 14
  • [46] DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling
    Li, Heng
    Li, Jian
    Zhang, Xianglei
    Feng, Chunlan
    Fan, Chen
    Yang, Xiaoqian
    Zhang, Rui
    Zhu, Fenghua
    Zhou, Yu
    Xu, Yechun
    Liu, Hong
    Tang, Wei
    BIOCHEMICAL PHARMACOLOGY, 2020, 177
  • [47] Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
    Perez-Aso, Miguel
    Montesinos, M. Carmen
    Mediero, Aranzazu
    Wilder, Tuere
    Schafer, Peter H.
    Cronstein, Bruce
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [48] Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
    Miguel Perez-Aso
    M. Carmen Montesinos
    Aránzazu Mediero
    Tuere Wilder
    Peter H. Schafer
    Bruce Cronstein
    Arthritis Research & Therapy, 17
  • [49] Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)
    Grootendorst, DC
    Gauw, SA
    Benschop, N
    Sterk, PJ
    Hiemstra, PS
    Rabe, KF
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2003, 16 (06) : 341 - 347
  • [50] The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1-and Th17-polarizing cytokines in human dendritic cells
    Gianello, Veronica
    Salvi, Valentina
    Parola, Carmen
    Moretto, Nadia
    Facchinetti, Fabrizio
    Civelli, Maurizio
    Villetti, Gino
    Bosisio, Daniela
    Sozzani, Silvano
    BIOCHEMICAL PHARMACOLOGY, 2019, 163 : 371 - 380
12345